846 related articles for article (PubMed ID: 17596173)
21. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
22. Malignant melanoma in Turkey: a single institution's experience on 475 cases.
Tas F; Kurul S; Camlica H; Topuz E
Jpn J Clin Oncol; 2006 Dec; 36(12):794-9. PubMed ID: 17060409
[TBL] [Abstract][Full Text] [Related]
23. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
Barnhill RL; Fine JA; Roush GC; Berwick M
Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
[TBL] [Abstract][Full Text] [Related]
24. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.
Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103
[TBL] [Abstract][Full Text] [Related]
25. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis.
Kageshita T; Kuriya N; Ono T; Horikoshi T; Takahashi M; Wong GY; Ferrone S
Cancer Res; 1993 Jun; 53(12):2830-3. PubMed ID: 8504426
[TBL] [Abstract][Full Text] [Related]
26. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
27. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
[TBL] [Abstract][Full Text] [Related]
28. Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.
Petitt M; Allison A; Shimoni T; Uchida T; Raimer S; Kelly B
J Am Acad Dermatol; 2009 Nov; 61(5):819-28. PubMed ID: 19836642
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in patients with thick cutaneous melanoma (> 4 mm).
Zettersten E; Sagebiel RW; Miller JR; Tallapureddy S; Leong SP; Kashani-Sabet M
Cancer; 2002 Feb; 94(4):1049-56. PubMed ID: 11920475
[TBL] [Abstract][Full Text] [Related]
30. The prognostic importance of sentinel lymph node biopsy in thin melanoma.
Ranieri JM; Wagner JD; Wenck S; Johnson CS; Coleman JJ
Ann Surg Oncol; 2006 Jul; 13(7):927-32. PubMed ID: 16788753
[TBL] [Abstract][Full Text] [Related]
31. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled study.
Sartore L; Papanikolaou GE; Biancari F; Mazzoleni F
Int J Surg; 2008 Jun; 6(3):205-9. PubMed ID: 18417434
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
[TBL] [Abstract][Full Text] [Related]
34. Osteopontin as a molecular prognostic marker for melanoma.
Rangel J; Nosrati M; Torabian S; Shaikh L; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Cancer; 2008 Jan; 112(1):144-50. PubMed ID: 18023025
[TBL] [Abstract][Full Text] [Related]
35. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma.
Hoersch B; Leiter U; Garbe C
Br J Dermatol; 2006 Oct; 155(4):771-7. PubMed ID: 16965427
[TBL] [Abstract][Full Text] [Related]
36. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
37. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
38. Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy?
Ito T; Wada M; Nagae K; Nakano-Nakamura M; Nakahara T; Hagihara A; Furue M; Uchi H
J Am Acad Dermatol; 2015 Jan; 72(1):71-7. PubMed ID: 25455840
[TBL] [Abstract][Full Text] [Related]
39. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center.
Azzola MF; Shaw HM; Thompson JF; Soong SJ; Scolyer RA; Watson GF; Colman MH; Zhang Y
Cancer; 2003 Mar; 97(6):1488-98. PubMed ID: 12627514
[TBL] [Abstract][Full Text] [Related]
40. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
